When screening for Down's syndrome using biochemical markers, the measurements are adjusted for the gestational age of the fetus because the concentrations of the markers are known to change with gestational age. This adjustment is performed by referring each marker measurement to the population median for that marker for the appropriate estimated gestational age group. The measurement of gestational age is subject to error, whichever method is used, and so the population median used is usually the median of a mixture of distributions for different true gestational ages. Most screening programmes aim for a specific number of weeks and this produces a concentrated distribution of true gestational ages. This fact, combined with dating errors, leads to an asymmetric mixture for each gestational age group and hence to bias in the estimates of the medians. In a previous communication we have shown how the proportions in this mixture distribution can be estimated and how the true medians corresponding to a true gestational age can be estimated. The calculations presented were performed using a single marker, and the details of our method were restricted to this situation. This paper extends the method to the multimarker situation and, as expected, leads to a gain in the detection rate for a specified false positive rate. The true patient-specific risk estimates are again markedly different from the quoted nominal value obtained by ignoring the dating errors. The data set on which the method is illustrated uses two markers, although the technique generalises in an obvious way to more than two.
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For many years it has been recognized that analytes used in screening for Down's syndrome, such as maternal serum z-fetoprotein (MSAFP) and human chorionic gonadotrophin (HCG), vary with the estimated gestational age of the fetus.' While it has been recognized that gestation dating is not exact, and some have attempted to estimate the effect of this variability on certain risk factors.? until recently! no one has fully quantified the effect of dating errors. We have shown;' for a single analyte, how these dating errors affect the medians for different estimated gestational age groups, which in turn affect the calculations of the multiples of the median (MoMs) and patient-Correspondence Dr A B J Nix. specific risks. The methods we proposed enabled the true medians to be estimated by identifying the true age-dependent distributions. The calculations were illustrated by using MSAFP measurements taken from the database provided by the Royal Gwent Hospital screening programme for Down's syndrome. At this centre the target gestational age for screening was 16 weeks and the majority of women reported with an estimated gestational age of 16 or 17 weeks. The dating errors, combined with this concentration of estimated gestational ages, meant that many of those at, say, 15 weeks would in fact have a true gestational age of 16 weeks but have been misclassified, leading to errors in estimating the true medians. We found that, for MSAFP, the true medians could differ by as much as 14% from those currently being used, the discrepancy between the two sets of medians being greatest at the extremes of the gestational ages occurring in the screening programme. While the magnitudes of these effects are consequences of the particular screening programme in use, the principles outlined would apply to any screening protocol. We also indicated the impact of these calculations on the detection rate (DR) and false positive rate (FPR), these being dependent on estimated gestational age. We concluded that, while a slight increase in the average detection rate would follow from our approach using a single analyte, the main effect, from a patient's point ofview, was that the estimated risk could be quite different from that calculated by conventional methods. In this paper we outline the necessary extension of the technique to embrace the multivariate case, when more than one marker is used. The database from the Royal Gwent Hospital had paired measurements for MSAFP and HCG and so this bivariate situation is the one analysed here, although the method can be extended in an obvious manner to cover more markers.
METHODS
We begin by recalling some of the basic notation and terminology of our earlier paper.' We use the notation EGA for an estimated gestational age and TGA for a true gestational age, and assume both are recorded in whole weeks.
First the basic screening algorithm is based on the result Posterior odds = Likelihood ratio x Prior odds where the likelihood ratio is calculated using an appropriate distribution, the dimensionality reflecting the number of analytes involved in the screening test. The distribution is usually taken to be Gaussian and this is the case here. The prior odds are derived from a maternal agedependent prior risk, usually taken as: 4 Probability (Down's fetus given maternal age m)
The test result is deemed positive if the posterior odds are greater than some threshold, such as 1:300.
Misclassification Distribution This is the probability distribution followed by the EGA for a given TGA. For ultrasound measurements we obtained the following results, Ann Clin Biochem 1997: 34
Prob(EGA=x weeks given TGA=x weeks) =0,772
Prob(EGA = x ± 1 week given TGA = x weeks) = 0·114 Prob(EGA>x+l weeks or EGA<x-l weeks given TGA = x weeks) = 0-000017 and therefore misclassification was assumed to occur only up to ± I week with correct classification occurring 77·2% of the time. Other distributions can be obtained corresponding to other dating techniques such as last menstrual period (LMP). From this distribution it was shown how to calculate the probabilities P« (the probability that TGA = i weeks given EGA = t weeks), a quantity central to most calculations.
Probability distribution for TGA Because of the screening protocol used at the Royal Gwent, only TGAs of IS, 16, 17, 18, and 19 weeks were felt to be appropriate by the clinicians. In our previous paper,' we denoted the probability of TGA over these weeks by PIS, . . . ,P19 and illustrated how these could be estimated using a minimum X 2 criterion.
TGA dependent parameters
In our earlier paper we only considered the single analyte MSAFP and defined Xi to be the MSAFP reading at a TGA of i weeks. The assumed logarithmic normality of MoMs means that 10g,,(X;) has the Gaussian distribution N(J.lj,a 2), where u, denotes the mean of 10g,,(X;) and a is the standard deviation. If Z, denotes log,,(X,) at an EGA of t weeks then the u, can be estimated by solving the equations
The common variance a 2 is found by solving the more complicated equation
In the context of this paper these equations would need to be solved for each analyte that is used in the screening procedure. The above is sufficient to determine the EGA and maternal age-dependent detection and false positive rates for a single marker. To extend the method to the multivariate case requires a method for estimating the true correlation coefficients between the markers used, so that the multivariate likelihood ratio can be calculated. and u~can be estimated in the way indicated using the single analyte measurements associated with MSAFP and HCG. It can be shown" that the correlation coefficient at an EGA ofk weeks, p(k), can be estimated from the equation
where the summation over j is from k-I to k + 1, due to the assumption that misclassification is restricted to ± I week. Assuming that the correlation between the two measurements is independent of EGA, an overall estimate of the common correlation coefficient p is obtained by taking a weighted average of estimates from each EGA group. For the Royal Gwent data p(k) was not found to depend on k and the weighted estimate of p was 0·200 for healthy fetuses, which is slightly higher than the observed correlation coefficient of 0·178. We would expect the observed value for p to be lower than the true value because the mixing effects will increase the effective standard deviations and hence reduce p. We also note that there are a number of different estimates of the correlation coefficient between 10g.,(MoM(MSAFP)) and 10ge(MoM(HCG» for healthy fetuses in the literature, a point discussed in more detail later, and so the calculations presented here should be viewed primarily as an indication of the possible magnitude of the effects we have described.
RESULTS
The methods outlined earlier are sufficient to estimate the mixture distributions for the healthy fetuses and the true parameter values for the assumed multivariate normal form of the distribution of log(MoM(MSAFP» and log(-MoM(HCG». Having obtained these parameter values it is now possible to calculate the patient specific risks and FPRs and DRs. The mathematical detail of these calculations has been recorded elsewhere' and so will not be repeated here.
For MSAFP, using Wald's 1992 paremeters," the maternal age dependent FPR and DR, together with their average values are shown in Table I . To facilitate comparisons between the efficiencies of different combinations of markers we have adjusted the risk thresholds to produce the same average FPR of 5% for each screening test. The first row is using Wald's approach and the second row is using the approach we have described using the mixture distributions. As can be seen, the age-dependent FPRs and DRs are slightly different for the two approaches, resulting in a slight increase in the average DR using our approach. Table 2 displays similar figures for HCG using Wald's 1992 parameters, again adjusted to give a FPR of 5%. Again there is a slight increase in the average DR using our approach. If use is made of both markers the results are shown in Table 3 . As can be seen the average DR has increased by 1·14%, approximately equal to the sum of the two separate gains. It is also noticeable that the magnitude of the gain is dependent on the maternal age and seems to peak at 35 years of age, where the differential gain is approximately 1·65%.
The data presented in Tables 1-3 have been calculated on the assumption that the parameter values used to describe the variance--eovariance terms for the Down's population are equal to those of the healthy population. Table 4 shows the standard deviations of 10g.,(MoM(AFP)) and 10g.,(MoM(hCG)) and the correlation coefficient between them in both healthy and Down's cases quoted in a selection of papers.v"? together with the P-value of the hypothesis test, using Box's M test, 11 for equality of the covariance matrices in the two groups. The results are mixed, in that three of the five studies quoted give nonsignificant results while the other two give significant results. There is also considerable variation between the results of these studies, and the differences between the covariance matrices for one set of controls compared with Ann Clin Biochem 1997: 34 another set are in several cases far more significant than the differences between the Down's cases and controls. If the assumption of equality is not made, then it is difficult to choose an obvious alternative, given the results in Table 4 . We therefore made the assumption of equality. The methodology we have described still applies in the case of unequal covariance structure; the only difference is that in that case the DR and FPR cannot be determined analytically and simulation techniques must be employed.l It is interesting to note that the values in the healthy population vary considerably between studies, and this is rather surpris- 
False positive rates ( FP R; %) and detection rates (DR; %) for MSAFP, averaged over all gestational agesJar a range ofmaternal ages using: (a) Wald's method with a risk cut-offof 1/268, and (h) the proposed method using a cut-off of 1/289. The final column is a weighted average (WA) using the maternal age distribution from the Royal Gwent data

CONCLUSION
In this paper we have addressed the problem of extending the single analyte mixture models, outlined in an earlier communication, to the multimarker situation. We have shown how to estimate the true correlation coefficient between any pair of markers for each true gestational age group. Having identified the true correlation coefficient, the complete set of parameter values needed to determine the multivariate normal form of the joint marker readings is now known. This in turn enables the patient-specific risks to be determined in the multimarker situation and so extends our previous results. With reference to the database from the Royal Gwent Hospital the main effect that our analysis emphasizes is the impact that dating error has on the calculation of patient-specific risks. Ignoring dating error leads to an over-estimate of the risk in younger mothers and an underestimate in older mothers. Correcting for these errors means that fewer young women will be referred and more older women, leading to higher false positive rates and detection rates in the older mothers and lower ones in the younger mothers.
Since the detection rate is much higher in older women than in younger ones, this switch towards a higher proportion of older women being referred also leads to a small overall increase in the average detection rate. and hence fewer Down's cases being detected, the reverse being true for older women. It is also worth noting how, to preserve a fixed FPR of 5%, the threshold risk values change according to the marker, or combination of markers, used. This raises the interesting question as to whether patient-specific risk thresholds should be set by reference to population parameters such as average FPRs or not. This point is discussed by Bishop et al. 14 Figure I certainly illustrates the impact on the threshold risk values should such a policy be adopted. ing since some of these are based on quite large samples, so that standard errors are small. Some would argue that these discrepancies are associated with the way the results have been calculated, particularly the removal of between batch effects for those databases that have used stored samples.'? We do not wish to pursue this issue in this publication but feel that more attention needs to be paid to the standardization of the collection of data and how it is recorded on a common scale of measurement (MoM).l3
We commented in our first paper that the greatest impact that our approach has is on the calculation of patient-specific risks. These are dependent on both the EGA and the maternal age of the patient. For illustrative purposes we have plotted, in Fig. I , the true risk thresholds using our approach against the equivalent nominal value using Wald's approach for a patient with an EGA of 16 weeks. The true risk thresholds are seen to be very different for patients at the extremes of the age range. For younger women the risk threshold is seen to be much lower than the nominal value quoted, thus resulting in fewer such patients being referred
